Craft

10X Genomics

Stock Price

$15.8

2024-10-29

Market Capitalization

$1.9 B

2024-10-29

Revenue

$642.8 M

FY, 2025

10X Genomics Summary

Company Summary

Overview
10X Genomics is a company building products for research institutions and pharmaceutical companies across the life sciences, including oncology, immunology, and neuroscience. It offers the Chromium platform that enables analysis of individual biological components and multiomic readouts including gene expression, protein, chromatin, and antigens. The Visium platform includes Spatial Gene Expression, HD Spatial Gene Expression, and Spatial Gene and Protein Expression assays as well as the Visium CytAssist, an instrument designed to manage Visium solution workflow. The Xenium platform enables researchers to detect the location of each fluorescent probe.
Type
Public
Status
Active
Founded
2012
HQ
Pleasanton, CA, US | view all locations
Website
https://www.10xgenomics.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Serge Saxonov

    Serge Saxonov, Chief Executive Officer, Co-Founder

  • Ben Hindson

    Ben Hindson, Chief Scientific Officer, Co-founder, President

  • Michael Schnall-Levin

    Michael Schnall-Levin, Chief Technology Officer, Founding Scientist

  • Justin McAnear

    Justin McAnear, Chief Financial Officer

Operating MetricsView all

Revenue per Installed Instrument

$158K
6.8%

FY, 2019

Instruments Installed to Date

1.7K
63.2%

FY, 2019

Countries

40

FY, 2019

LocationsView all

5 locations detected

  • Pleasanton, CA HQ

    United States

    6230 Stoneridge Mall Rd

  • San Francisco, CA

    United States

    Three Embarcadero Center #2330

  • Shanghai, Shang Hai Shi

    China

    1018 Chang Ning Lu, Chang Ning Qu

  • Leiden, ZH

    Netherlands

    Dellaertweg 9D

  • Singapore

    Singapore

    164 Kallang Way, #09 12 18

10X Genomics Financials

Summary Financials

Revenue (Q1, 2026)
$150.8M
Gross profit (Q1, 2026)
$106.2M
Net income (Q1, 2026)
($13.5M)
Cash (Q1, 2026)
$490.3M
EBIT (Q1, 2026)
($17.0M)
Enterprise value
$1.5B

Footer menu